logo-loader
viewCB2 Insights Inc.

CB2 Insights delays publishing financial reports until on or about June 12 due to coronavirus pandemic

CB2 pointed out that its clinical services remain open to servicing patients in each operating State, currently via telehealth and telemedicine

Telemedicine
The company said it continues to be focused on execution with a current focus on cash management for operations and staff

CB2 Insights Inc. (CSE:CBII) (OTCQB:CBIIF) has said that, due to circumstances created by the coronavirus (COVID-19) pandemic it will not be filing its financial statements for the fiscal year ended December 31, 2020 by the scheduled due date of April 30, 2020.

The company said it expects to file the financial reports on or about June 12, 2020, and until then, as required, its management and other insiders will be subject to a trading black-out.

READ: CB2 Insights launches medical cannabis industry’s first interactive dashboard to offer patient insights

Other than as previously disclosed, the company added, there have been no material business developments since the date of its most recent filing of its interim financial statements.

CB2 pointed out that its clinical services remain open to servicing patients in each operating State, currently via telehealth and telemedicine due to State requirements for respecting social distancing.

The company said it continues to be focused on execution with a current focus on cash management for operations and staff.

It concluded: "With the uncertainty of COVID-19 and its impact both in the short and long-term to all businesses, the Company wants to certainly provide confidence to our investment community to continue to execute in the best way possible, and deal with the intermittent challenges in order to ensure CB2 Insights achieves its long-term objectives."

Quick facts: CB2 Insights Inc.

Price: 0.095 CAD

CSE:CBII
Market: CSE
Market Cap: $7.87 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CB2 Insights Inc. named herein, including the promotion by the Company of CB2 Insights Inc. in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CB2 Insights announces key partnership with GL Brands for...

CB2 Insights ((CSE: CBII; OTCQB: CBIIF) CEO Prad Sekar joined Steve Darling from our Toronto studio to provide details the will begin a prospective trial with GL Brands that will assess the safety, efficacy and other health measures for patients using Green Lotus’ cannabidiol soft gel capsules...

on 12/17/2019

2 min read